Hope on the Horizon: Emerging Treatment Options for Patients with Retinopathy of Prematurity

FACULTY

Audina M. Berrocal, MD
Professor of Clinical Ophthalmology
Medical Director of Pediatric Retina and ROP
Vitreoretinal Fellowship Director, Bascom Palmer Eye Institute
Miami Miller School of Medicine, University of Miami
Miami, FL

PROGRAM OVERVIEW

This enduring program about retinopathy of prematurity (ROP) targets key concepts about pathophysiology and the role of vascular endothelial growth factor (VEGF), screening, and management for this potentially visually blinding disorder of premature infants. Learn essential elements for recognizing infants at risk, timelines to ROP development, current advances in treatment approaches and critical examination timeframes to help prevent progression as well as complications of advanced disease.

TARGET AUDIENCE

This activity is designed to meet the needs of pediatric ophthalmologists, neonatologists, pediatricians, ophthalmologists, retina specialists, ophthalmology residents and fellows, and other healthcare providers who are involved in the care of patients with or at risk for ROP.

LEARNING OBJECTIVES

  • Examine the physiological rationale for the use of anti-VEGF therapies in infants with ROP
  • Compare the efficacy of anti-VEGF therapies and laser photocoagulation for ROP
  • Evaluate the safety of laser photocoagulation and anti-VEGF therapies in infants with ROP

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses who are involved in the care of patients with or at risk for ROP.
CNE Credits: 1.0 ANCC Contact Hour.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Audina M. Berrocal, MD, discloses that she has received consulting fees from Alcon, Dutch Ophthalmic Research Center (DORC), and Oculus Pharmaceuticals.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
  • Jessica Feygin, Program Coordinator of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Nicole Longo, DO, FACOI, Medical Director for Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
  • Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top